Back to discover
Disease
Dry Eye Syndromes
Late-stage therapeutic developmentEmerging research
1
Publications
16
Clinical trials
12
Associated genes
2017
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Clinical trial2026-08-27Status changed to Completed · ClinicalTrials.gov
Clinical trial2026-08-14Results posted · ClinicalTrials.gov
Clinical trial2026-08-14Status changed to Completed · ClinicalTrials.gov
Clinical trial2026-07-27Status changed to Completed · ClinicalTrials.gov
Clinical trial2026-07-14Status changed to Completed · ClinicalTrials.gov
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 3 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
- Q4 2026Photobiomodulation of the Ocular Surface and Eyelids With Different Wavelengths: REd vs BluE Light (REBEL)
- Q4 2026The Protective Impact of TheaLoz Duo Eyedrop on the Ocular Surface in Hand-Held Console and Computer Game Users
- Q3 2028Clinical Study of Mesenchymal Stem Cell Eye Drops for Treating Dry Eye Disease
Major developments
Upcoming trial readoutImportant
Results expected Q3 20282026-04-15
Upcoming trial readoutImportant
Results expected Q4 20262026-01-21
Clinical MilestonesViewHide
Results expected
- 2026-04-15Clinical Study of Mesenchymal Stem Cell Eye Drops for Treating Dry Eye DiseaseResults expected Q3 2028
- 2026-01-21Photobiomodulation of the Ocular Surface and Eyelids With Different Wavelengths: REd vs BluE Light (REBEL)Results expected Q4 2026
- 2026-01-21The Protective Impact of TheaLoz Duo Eyedrop on the Ocular Surface in Hand-Held Console and Computer Game UsersResults expected Q4 2026
Recently completed
Activity timeline4
- 2026-04-15ClinicalClinical Study of Mesenchymal Stem Cell Eye Drops for Treating Dry Eye DiseaseResults expected Q3 2028
- 2026-01-21ClinicalPhotobiomodulation of the Ocular Surface and Eyelids With Different Wavelengths: REd vs BluE Light (REBEL)Results expected Q4 2026
- 2026-01-21ClinicalThe Protective Impact of TheaLoz Duo Eyedrop on the Ocular Surface in Hand-Held Console and Computer Game UsersResults expected Q4 2026
- 2026-01-01ClinicalA Clinical Study for Safety and Efficacy Evaluation of Limbal Stem Cell Derived Exosome (LSC-Exo) Eye Drop for Treatment of Dry Eye SyndromePrimary completion
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approved & established therapies
Imetelstatapproved
Approval — Treatment of transfusion-dependent anaemia in adults with low- to intermediate-1 risk mye… (2025)
Pegfilgrastimapproved
Approval — Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adul… (2025)
Azacitidineapproved
Approval — Azacitidine Kabi is indicated for the treatment of adult patients who are not eligible fo… (2024)
Efbemalenograstim alfaapproved
Approval — Ryzneuta is indicated for the reduction in the duration of neutropenia and the incidence… (2024)
Lenalidomideapproved
Approval — Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatme… (2021)
Luspaterceptapproved
Approval — Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to… (2020)
Clinical trials
The current development programme across all trial phases.
Clinical programme
16
4
9
6
Late-stage studies
Recruiting
Recently completed
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
First approvals
2025emaApproval — Pegfilgrastim· Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). source ↗
2025emaApproval — Pegfilgrastim· Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). source ↗
2025emaApproval — Imetelstat· Treatment of transfusion-dependent anaemia in adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). source ↗
2024emaApproval — Efbemalenograstim alfa· Ryzneuta is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). source ↗
2024emaApproval — Azacitidine· Azacitidine Kabi is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation(HSCT) with: Intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the international prognostic scoring system (IPSS), Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder, Acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification, AML with > 30% marrow blasts according to the WHO classification. source ↗
2021emaApproval — Lenalidomide· Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1). Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1). Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). source ↗
2020emaApproval — Pegfilgrastim· Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). source ↗
2020emaApproval — Luspatercept· Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia. Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia. source ↗
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Recent publications
Major themes1
- Dry Eye Syndromes1
Leading journals1
- The ocular surface1
Leading researchers8
- Azar DT1
- Belmonte C1
- Bron AJ1
- Chauhan SK1
- Craig JP1
- de Paiva CS1
- Gomes JAP1
- Hammitt KM1
Affiliations (unnormalised)6
- Baylor College of Medicine1
- Centre for Contact Lens Research1
- Federal University of Sao Paulo/Paulista School of Medicine1
- HealthPartners Medical Group and Clinics1
- Instituto de Neurociencias de Alicante1
- New Zealand National Eye Centre1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Corneal and conjunctival dryness due to deficient tear production, predominantly in menopausal and post-menopausal women. Filamentary keratitis or erosion of the conjunctival and corneal epithelium may be caused by these disorders. Sensation of the presence of a foreign body in the eye and burning of the eyes may occur.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.